Lipid CME

Optimizing LDL-C Reduction with Oral Therapy: Featuring the Wheel of Knowledge Challenge

Author(s)/Faculty: Peter H. Jones, MD, FACP, FNLA; Gina Price Lundberg, MD, FAHA, FACC; Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Release Date: 11/5/2021Expiration Date: 11/4/2022
Credit Type: CME / CME WITH ABIM MOCNumber of Credits: 1.25
Content Type: LectureProvider:
In the United States, cardiovascular disease is the leading cause of death, claiming over 800,000 lives annually. Dyslipidemia is a major risk factor for adverse cardiovascular outcomes, with 30% of US adults having elevated LDL-C (≥130 mg/dL). While many patients with elevated LDL-C benefit from statin therapy, about 10% to 30% have statin intolerance or dose-limiting toxicities, leaving them at risk for adverse cardiovascular events. Add-on medications may further reduce LDL-C for these patients; however, clinicians may not be knowledgeable about the benefits of these drugs. In this educational activity featuring the fun and engaging Wheel of Knowledge Challenge, expert clinicians discuss the latest updates regarding LDL-C–lowering medications.